Share Name Share Symbol Market Type
Johnson and Johnson NYSE:JNJ NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -0.43 -0.26% 166.67 168.72 166.3165 167.20 4,198,720 20:55:58

AC Immune Sees Positive Data in Trial for Alzheimer's Disease Treatment

12/11/2021 2:44pm

Dow Jones News

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

From Oct 2021 to Jan 2022

Click Here for more Johnson and Johnson Charts.

By Chris Wack


AC Immune SA said it saw positive new interim Phase 1b/2a data on ACI-35.030, a first-in-class anti-phosphorylated-Tau vaccine candidate being developed in partnership with Janssen Pharmaceuticals Inc.

The company said ACI-35.030 is the first Alzheimer's disease vaccine candidate designed to generate antibodies targeting pathological pTau in the brain.

AC Immune said results from the trial show that ACI-35.030 treatment led to the strong induction of antibodies specific for pathological forms of Tau such as pTau and its aggregated form, enriched paired helical filaments. Anti-pTau IgG titers increased by two orders of magnitude from baseline already two weeks after the first injection of the mid-dose of ACI-35.030.

Interim safety data further support ACI-35.030's favorable safety and tolerability profile, with no clinically relevant safety concerns observed to date.

As previously reported, the ongoing Phase 1b/2a study has been expanded to include a total of 24 Alzheimer's disease participants in the mid-dose sub-cohort. This expansion was designed to support the advancement of ACI-35.030 into late-stage development.

AC Immune shares were up 11% to $6.70 in premarket trading.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

November 12, 2021 09:29 ET (14:29 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

1 Year Johnson and Johnson Chart

1 Year Johnson and Johnson Chart

1 Month Johnson and Johnson Chart

1 Month Johnson and Johnson Chart
ADVFN Advertorial
Your Recent History
Johnson an..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220119 21:10:58